Similar articles

• [Clinical effects of NK 631 (pepleomycin) against malignant tumors of the head and neck (author's transl)].

  Satoh F, Saitoh H, Mizukoshi O. Satoh F, et al. Jpn J Antibiot. 1979 Jul;32(7):751-5. Jpn J Antibiot. 1979. PMID: 90743 Japanese.
• [Primary effect of NK 631 against head-and-neck cancers (author's transl)].

  Takata K, Honda T. Takata K, et al. Jpn J Antibiot. 1979 Jan;32(1):106-14. Jpn J Antibiot. 1979. PMID: 84880 Japanese. No abstract available.
• [Histological appearances of cancer of the head and neck treated with pepleomycin (NK 631) (author's transl)].

  Matsumura Y, Nomura Y, Eguchi S, Yanagita T. Matsumura Y, et al. Jpn J Antibiot. 1978 Nov;31(11):651-8. Jpn J Antibiot. 1978. PMID: 83401 Japanese.
• A review of clinical studies of pepleomycin.

  Oka S. Oka S. Recent Results Cancer Res. 1980;74:163-71. doi: 10.1007/978-3-642-81488-4_21. Recent Results Cancer Res. 1980. PMID: 6160600 Review.
• Current status of American studies with bleomycin.

  Carter SK, Blum RH. Carter SK, et al. Prog Biochem Pharmacol. 1976;11:158-71. Prog Biochem Pharmacol. 1976. PMID: 63960 Review. No abstract available.